John Bradley Sorenson Sells 6,389 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson sold 6,389 shares of the company’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.06, for a total value of $671,228.34. Following the transaction, the executive vice president now directly owns 24,293 shares in the company, valued at approximately $2,552,222.58. The trade was a 20.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

John Bradley Sorenson also recently made the following trade(s):

• On Friday, February 7th, John Bradley Sorenson sold 6,528 shares of Boston Scientific stock. The shares were sold at an average price of $104.97, for a total value of $685,244.16.
• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The shares were sold at an average price of $90.02, for a total value of $370,792.38.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $106.20 on Friday. The stock has a 50 day moving average of $96.11 and a 200 day moving average of $87.97. Boston Scientific Co. has a 12 month low of $65.33 and a 12 month high of $107.17. The firm has a market cap of $156.51 billion, a PE ratio of 84.96, a PEG ratio of 2.79 and a beta of 0.80. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. On average, research analysts expect that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on BSX shares. Piper Sandler upped their price objective on Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. upped their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research report on Friday, January 10th. Finally, TD Cowen upped their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, December 12th. One analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $107.39.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. TFC Financial Management Inc. lifted its stake in shares of Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 210 shares during the last quarter. Global Wealth Strategies & Associates lifted its stake in shares of Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 250 shares during the last quarter. West Oak Capital LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $29,000. Dunhill Financial LLC lifted its stake in shares of Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 152 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $28,000. 89.07% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.